Skip to content

Role of Acetylcysteine in Creatinine Clearance

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00396396
Enrollment
35
Registered
2006-11-06
Start date
2006-10-31
Completion date
Unknown
Last updated
2006-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Creatinine Clearance

Keywords

Creatinine clearance, Acetylcysteine

Brief summary

The purpose of this study is to investigate the exact role of Acetylcysteine (Mucomyst) in altering creatinine clearance. Prior studies have shown the protective effects of Acetylcysteine on contrast-induced renal dysfunction. In these studies, Acetylcysteine lowered the incidence of serum creatinine elevation after administration of radiographic contrast agents. Not only was the increase in serum creatinine prevented, the studies also demonstrated a significant increase in creatinine clearance after administration of the agent. These prior studies did not evaluate if the increase in creatinine clearance was indeed from a protective benefit of Acetylcysteine in preserving the GFR versus simply increasing the proximal tubular creatinine secretion without actually affecting the GFR. We propose an experiment to help support our hypothesis that Acetylcysteine increases creatinine clearance via an increase in proximal tubular secretion of creatinine.

Interventions

DRUGAcetylcysteine

Sponsors

Eastern Virginia Medical School
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
Yes

Inclusion criteria

1. Between the ages of 18 and 79 years 2. In good general health 3. Able to provide informed consent

Exclusion criteria

1. Allergy to acetylcysteine or cimetidine, 2. Age less than 18 years or greater than 79 years of age, 3. Women of childbearing age and not able to use adequate contraception, or 4. Anyone currently on any medication that interferes with tubular secretion of creatinine such as trimethoprim-sulfamethoxazole (Bactrim).

Countries

United States

Contacts

Primary ContactRitche Chiu, MD
dr_ritchechiu@yahoo.com757-680-0211
Backup ContactMichael J Bradley, MD
BradleMJ@evms.edu757-554-5578

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026